NDAORALTABLETPriority Review
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Mechanism of Action
Opioid mu-Receptor Agonists
Pharmacologic Class:
mu-Opioid Receptor Agonist
Clinical Trials (5)
Investigation of Eluxadoline for Diabetic Diarrhea
Started Jul 2022
0Diabetic DiarrheaDiabetesDiarrhea
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Started Aug 2021
124 enrolled
Irritable Bowel Syndrome
Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence
Started Apr 2019
0Fecal IncontinenceAccidental Bowel LeakageAnal Incontinence+2 more
Eluxadoline Bile Acid Malabsorption (BAM) Study
Started Feb 2018
24 enrolled
Irritable Bowel Syndrome With Diarrhea
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
Started Nov 2017
95 enrolled
Irritable Bowel Syndrome
Loss of Exclusivity
LOE Date
Mar 14, 2033
85 months away
Patent Expiry
Mar 14, 2033